


CARBONIC ANHYDRASE INHIBITOR

- Acetazolamide and other CA inhibi. — more often use for their other action than DU effect.
- less efficacious than furosemide & loop.

ACETAZOLAMIDE MOA

- ⇒ Inhibit CA located intracellularly (cytoplasm) and on apical memb. of PT
- ⇒ CA — catalyse the rxn of CO_2 and H_2O

$$\text{H}_2\text{O} + \text{CO}_2 \xrightarrow[\text{Spontan.}]{\text{Oxid.}} \text{H}^+ + \text{HCO}_3^-$$
- ⇒ ↓ use ability to exchange Na^+ for H^+ in presence of Acetazo. ⇒ **Mild Diuresis**
- ⇒ HCO_3^- retain in lumen → **↑ urinary pH**
- ⇒ loss of HCO_3^- → **Hyperchloremic metabo. acidosis** & ↓ use DU efficacy following several days of therapy
- ⇒ phosphate excretion → ↑ use by unknown mechanism



Therap. uses

Glaucoma


- Acetaz. ↓ use production of aq. humor & ↓ use IOP in pts w/ **chronic open-angle glaucoma** — Blocking CA in ciliary body of eye
- Topical CA inhibitor — NOT cause systemic effects
 - ↳ Dorzolamide
 - ↳ Brinzolamide

Motion Sickness (like Scopolamine)

- use in prophylaxis
- prevent weakness, breathlessness, Dizziness, Nausea and **cerebral** as well as **pulmonary edema**

* KINETICS:

- ✓ Adm. orally
- ✓ **90% PAB**
- ✓ Eliminated by both active tubular secretion & passive reabsorp.



ADVERSE - EFFECTS

- Metabolic acidosis (mild)
- K^+ depletion
- Renal stone formation
- Drowsiness & paresthesia (abnormal sens. of skin e.g. tingling, pricking, chilling, burning & numbness)
- Avoid in pts w/ **hepatic cirrhosis**, because it could lead to ↓ use excretion of NH_4^+

Pharmacology - study YouTube

LOOP OR HIGH CEILING DIURETICS

- Site of action: Ascending LOH
- Furosemide - most commonly used
- Bumetanide & torsemide - are more potent (their use is increasing)
- Ethacrynic acid - infrequently used (ADR profile)

MOA

Inhibit $\text{Na}^+/\text{K}^+/\text{2Cl}^-$ co-transport in luminal membr. in ascending limb of LOH

Ascending limb account for 25-30% of filtered NaCl - downstream sites're unable to compensate for ↑ se Na^+ load

greatest DU effect of all drugs.

ACTION

Pharmaco-study YouTube

Act promptly even in pt. w poor renal function or lack of resp. to other diureti

- ↑ se Ca^{2+} content in urine
- In pt. w normal serum Ca^{2+} hypocalcemia doesn't occur bcoz Ca^{2+} reabsorb. in DCT

- ↑ RBF, possibly by ↑ing Prostagl. synthesis
- NSAIDs (may ↓ use prostag. sy.)
- ↓ se DU action

Therapeutic uses

Acute pulmonary edema + acute/chronic periph. edema from HF or renal imp.

- (Drug of choice)
- given IV in emergency
- Lasix (Tab + inj) = furosemide

Hypercalcemia (Loop DU + hydration) treat Hypercal.

Hyperkalemia

HT (rarely used alone) ↓ renal vascular res.

KINETICS

- Oral + IV
- DOA (2-4 hrs)

secreted in urine. ↑ RBF

ADRS

Ototoxicity

- Permanent or reversible Ototoxi, particularly w Ototoxic drugs (Aminoglycos. or Cisplatin)
- Ethacrynic acid is most common causative agent
- Induce vertigo

Hyperurkemia

Furosemide & E.A. compete w uric acid for renal secretory system
↓
exacerbating Gouty attack

Acute Hypovole.

- Hypotension
- Shock
- Cardiac arrhy.

K⁺ depletion

Heavy load of Na^+ presented to CT results in ↑ se exchange of Na^+ & K^+ → Hypokalemia
• Loss of K^+ from cells in exchange for H^+ lead to Hypokalemic alkalosis

Hypomagnes.

Chronic use ↓ dietary Mg^{2+}
↓
Hypomagne. (Particular in elder)
Supplement & oral mag.

(K⁺ sparing DU or supplementation w K^+ can prevent this)

POTASSIUM-SPARING DIURETICS

- Site of action = collecting Tubule ^{late distal} - Inhibit Na^+ reabs & K^+ excretion
- Major use $\rightarrow$ HT (in combinⁿ wth thiazide) - Avoided in pt wth renal dysfunc. because of $\uparrow$ risk of Hypokalemia
- Types, of class: (1) Aldo. antag. (2) Na^+ channel blocker.

* ALDO. ANTAG: Spironolac. & eplerenone

MOA (Synth. steroid)

Spironolac. antagonize Aldo. at intracellular cytoplasmic receptor site

Rendering spiro-recep. complex inactive
prevent translocation of complex into nucleus of target cell $\rightarrow$ failure to produce mediator protein that normally stimulate Na^+/K^+ exchange site of CT $\rightarrow$ Thus lack of m. protein prevent Na^+ reabs. and K^+ and H^+ secretion.

Transport Na^+ channel from cytoplasm to membra

Activate an inactive Na^+ channel

Form new Na^+ channel

ACTION: In edematous state = Aldosterone = Na^+ retention so spiro. uses NSAIDs diminish their effect.

* THERAPEUTIC USES

Diuretic

- Low Na^+ excrete efficiency
- High K^+ retention so use e other DU e.g. thiazides

Spironolac. DOC in pt wth hepatic cirrhosis, as edema in these pts is caused by secondary hyperaldosteronism

Secondary Hyperaldos.

- Secun. Hyperaldos. such as Hepatic cirrhosis & Nephrotic Syndrome

In pt. wth NO significant Aldo. level (e.g. Addison's disease), there is NO DU effect wth these drugs.

HF

- Prevent remodeling of heart due to HF
- $\downarrow$ se mortality also. wth HF (esp in pt. wth $\uparrow$ ejection fraction)

Resistant HT

defined as use of 3 or more medic without reaching the BP goal, often respond to K^+ -sparing (e.g. eplerenone, Aldo. level)

ASCITES

(complication of hep. cirrhosis)
Spironolac. = effective.

* KINETICS:

- abs. orally
- $\uparrow$ P/B/B
- metabo $\rightarrow$ Active metab. (DU also)
- Spironolac. $\rightarrow$ potent inhibi of P-glycoprotein
- eplerenone - metab by CYP450 (3A4)

PCOS

Block androgen receptor & inhibit steroid synthesis at high doses - helping to offset $\uparrow$ androgen level. (off-label use)

* ADRS

- Gastric upset
- Resemble sex steroids, may $\downarrow$ induce gynecomastia in male
- Mens. irregu. in female
- Hyperkalemia
- Nausea
- lethargy
- mental confusion
- Caution wth other K^+ drugs causing Hyperkalemia
- ACE-inhibitor
- K^+ supplement

TRIAMTERENE AND AMILORIDE

↓
+ Both block Na^+ -channel transport - CT

↓
Use Na^+/K^+ exchange

- NOT dependent on Aldosterone

⇒ Like Aldo. antag., they're not very efficacious DU
⇒ use in comb. w/ other DU

⇒ S.E.: ↑ se uric acid, renal stones & K^+ retention
(TZ & LOOP) (like AZM). (Aldo)


Pharmaco-study YouTube

THIAZIDE - DIURETICS - most widely used


- Sulfonamide derivatives - SITE OF ACTION = DCT, ascending LOH
- All have same efficacy $\rightarrow$ differ only in potency
- Sometimes called "low ceiling diuretics" bcoz $\rightarrow$ dose above normal dose $\neq$ $\uparrow$ response ^{Diuretic}
- chlor & Hydrochlorothiazide - reprints of Thiazide diuretic (same efficacy) (more potent)

* ChlorThalidone, indapamide and metolazone - Thiazide-like diuretics (Have sulfonamide residue in their chemical str - MOA is similar)


Mechanism



ACTION



THERAPEUTIC USES




* KINETICS:

- orally effective
- Take 1-3 weeks to produce stable $\downarrow$ in B.P
- Prolong $t_{1/2}$
- Secreted by organic acid secretory sys. of kidney

Thiazides $\rightarrow$ $\downarrow$ intravasc. vol $\rightarrow$ Activate RAAS $\rightarrow$ $\uparrow$ K^+ depletion

spironolactone / triamterene / amiloride $\rightarrow$ $\downarrow$ K^+ depletion

ADRS



Thiazid-Like Diuretics

- lack Thiazid structure
- But have unsubstituted sulfonamide group

- Therap. use & S.E are similar

Chlorthalidone

- long duration
- OD $\rightarrow$ For HT

Metolazone


- more potent
- Unlike Thiazides cause Na^+ excretion even in advanced renal failure

INDAPAMIDE

- Lipid-soluble
- long duration
- At low doses $\rightarrow$ show signif. antihypertensive minimal diuretic eff.

- metab. & excreted by GIT & Kidney Thus it is less likely to accumulate in pt w renal failure & may be useful in treatment

Pharmaco-study YouTube



- When cell becomes deficient in Na^+ , it starts taking Ca^{2+} from lumen & exchange it w Na^+ from blood $\rightarrow$ $\uparrow$ Ca^{2+} reabsorption.

✓ Metro is dapper in RF

• Metro & indap $\rightarrow$ dapper - RF

• dapper - Metro -

OSMOTIC DIURETICS

⇒ Simple, **Hydrophilic** chemical sub that're filtered through glomerulus e.g. MANNITOL AND URSA result in some degree of diuresis

⇒ presence of these sub. ⇒ High osmolality of tubular fluid
↓
prevent further water reabsorp.

↓
osmotic diuresis. & small amount of **Na⁺** loss.

⇒ Mostly use for **increasing water excretion** and rarely use in case of Na^+ retention

* Use to maintain urine flow following acute toxic ingestion of sub. capable of producing acute renal failure

* Mainstay treatment ⇒ ↑ increased ICP or ARF due to shock, drug toxicities & trauma

⇒ Maintaining urine flow preserve long-term kidney function
↓
Save pt. from dialysis

* Mannitol NOT abs. orally & Given IV.

ADVERSE EFFECTS:-

- EC water expansion
- Dehydration
- Hypo or Hypernatremia

⇒ Becoz the presence of Mannitol in ECF extract water from cells & causes hyponatremia until diuresis occur.